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Abstract
Objective—The examination of lung cancer by histology type is important for monitoring 
population trends that have implications for etiology and prevention, screening and clinical 
diagnosis, prognosis and treatment. We provide a comprehensive description of recent histologic 
lung cancer incidence rates and trends in the U.S. using combined population-based registry data 
for the entire nation.
Materials and Methods—Histologic lung cancer incidence data was analyzed from CDC’s 
National Program of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, 
Epidemiology and End Results (SEER) Program. Standardized rates and trends were calculated 
for men and women by age, race/ethnicity, and U.S. Census region. Rate ratios were examined for 
differences in rates between men and women, and annual percent change was calculated to 
quantify changes in incidence rates over time.
Results—Trend analysis demonstrate that overall rates have decreased, but incidence has 
remained stable for women aged 50 or older. Adenocarcinoma and squamous cell carcinoma were 
the two most common histologic subtypes. Adenocarcinoma rates continued to increase in men 
and women, and squamous cell rates increased in women only. All histologic subtype rates for 
white women exceeded rates for black women. Histologic rates for black men exceeded those for 
white men, except for small cell carcinoma. The incidence rate for Hispanics was nearly half the 
rate for blacks and whites.
Conclusion—The continuing rise in incidence of lung adenocarcinoma, the rise of squamous 
cell cancer in women, and differences by age, race, ethnicity and region points to the need to better 
understand factors acting in addition to, or in synergy with, cigarette smoking that may be 
contributing to observed differences in lung cancer histology.
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INTRODUCTION
Lung cancer, the leading cause of cancer deaths in the United States and the second most 
common cancer type for both men and women (1), is more than one disease. For reporting 
purposes, lung cancer is typically classified by two major histologic types: small cell lung 
cancer and non-small cell lung cancer (NSCLC). Adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma are the three main NSCLC subtypes. In the 1990s, 
pathologists tended not to report subtypes of non-small cell carcinomas since treatment and 
prognoses were considered similar. With the evolution of new advances in subtype 
classification and treatment, the classification of lung cancer by histology type became 
important for prognosis and choice of targeted therapies. The distinction between lung 
cancer histologic types also has implications for etiology and prevention, screening and 
clinical diagnosis, prognosis, and choice of treatment options (2–6).
In the United States, lung cancer incidence rates and trends by histologic type differ by sex 
and have shifted over time (7–11). From 1950 to early 1980, squamous cell carcinoma was 
most prevalent in men, and the most common type of lung cancer reported in U.S. tumor 
registries (9). Declining rates for squamous cell carcinoma were first noted in the 
mid-1980s, and this decline paralleled a decrease in smoking rates in the United States (8, 
11). National data from 2004 to 2006 indicate squamous cell carcinoma rates were more 
than twice as high for men than for women (12). Studies based on data from selected cancer 
registries noted an increase in the incidence of adenocarcinoma in both men and women 
beginning in the 1960s and 1970s (8, 10, 13). By the 1980s, the incidence rate of 
adenocarcinoma had surpassed that of squamous cell carcinoma (11). Data from the 1980s 
suggested a decline in adenocarcinoma incidence rates (14), especially among men younger 
than age 65 years, white women younger than age 45 years, and black women younger than 
age 55 years (11). A more recent analysis suggested a peak in adenocarcinoma incidence 
rates at the end of the 1990s (15). Since then, adenocarcinoma has remained the most 
common histologic subtype in men and women (12).
This study used 2004–2009 cancer data from population-based cancer registries for the 
entire U.S. population to provide a comprehensive description of recent lung cancer 
incidence rates with sufficient numbers to examine trends by histologic type by sex, age, 
race/ethnicity, and geographic region.
METHODS
We analyzed data from CDC’s National Program of Cancer Registries (NPCR) and the 
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program. 
Together, these two programs collate cancer incidence data for the entire U.S. population 
and the data are combined to create the United States Cancer Statistics (USCS) data set. In 
each U.S. state and the District of Columbia, cancer incidence data are collected from 
patient records at medical facilities (i.e., hospitals, physicians’ offices, therapeutic radiation 
facilities, freestanding surgical centers) and pathology laboratories and reported to NPCR or 
SEER central cancer registries. State-level incidence data must meet USCS high quality 
standards prior to publication: case ascertainment is 90% or more complete; no more than 
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5% of cases are ascertained solely on the basis of a death certificate; no more than 3% of 
cases are missing information on sex; no more than 3% of cases are missing information on 
age; no more than 5% of cases are missing information on race; and at least 97% of the 
registry’s records passed a set of single-field and inter-field computerized edits. Because 
data from Wisconsin were suppressed at the state’s request during 2004–2009, this report 
covers 98% of the U.S. population.
We restricted our analysis to lung and bronchus cancer cases diagnosed during 2004–2009 
because cancer stage is not comparable for cases diagnosed prior to 2004 (16). Initially, we 
identified 1,260,271 cases by using site codes C34.0–C34.9 from the International 
Classification of Diseases for Oncology, Third Edition (ICD-0-3) (17). We excluded cases 
without microscopic confirmation (12%), those identified through autopsy or death 
certificate only (0.1%), and those with a diagnosis code of sarcomas or other specific or 
unspecified cancer types (1.2%). We used ICD-0-3 morphology codes to define lung cancer 
histologic types for this study (see footnote of Table 2).
Incidence rates and temporal trends were calculated with SEER*Stat version 8.0.1 software 
(18). Because of sex differences in smoking habits and temporal trends for lung cancer, 
separate analyses were conducted for men and women. Incidence rates were standardized to 
the U.S. 2000 standard population, with population denominators estimated by SEER from 
the 2000 Census. Rates and percentages for men and women are presented by age group 
(<40 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and ≥80 years), race/
ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic American Indian/Alaska 
Native, non-Hispanic Asian/Pacific Islander, and Hispanic), U.S. Census region (Northeast, 
West, South, and Midwest), and histologic type (small cell carcinoma, squamous cell 
carcinoma, adenocarcinoma, large cell carcinoma, and other non-small cell carcinoma). Rate 
ratios were calculated to examine differences in lung cancer rates between men and women 
by demographic characteristics. Trends were examined by histologic type, and annual 
percent change (APC) was calculated to quantify the change in incidence rates over time, 
with a P value cutoff point of 0.05.
RESULTS
During 2004–2009, a total of 1,096,276 lung cancer cases were diagnosed and reported in 
the United States. The average annual incidence rate was 73.3 per 100,000 population 
among men and 49.4 among women. Among those with newly diagnosed lung cancer, 54% 
were men and 46% were women. Adenocarcinoma (44%) and squamous cell carcinoma 
(26%) accounted for the largest proportions of cases. Rates by patient characteristics—
including age, race/ethnicity, and U.S. Census region—for men and women are summarized 
in Table 1. The incidence of lung cancer was 1.5 times higher for men than for women. 
Rates for women younger than age 50 years were higher than the rates for men in this age 
group.
In addition to differences by sex, rate differences also were observed by race/ethnicity. Rates 
for non-Hispanic (NH) black men were about 20% higher than NH white men. Among both 
men and women, the rate for Hispanics was nearly half the rate for NH blacks and NH 
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whites. Men had higher incidence rates than women for race and ethnic groups, but the 
relative size of this difference by sex was higher for NH blacks, NH Asian/Pacific Islanders 
and Hispanics compared with NH whites. The relative difference in incidence rates between 
men and women was slightly lower for NH American Indian/Alaska Native (AI/AN) 
populations than for whites. Differences between men and women living in the West were 
less pronounced compared to those living in other regions (Table 1).
During 2004–2009, NSCLC made up 86% of lung cancers in men and 84% of lung cancers 
in women (Table 2). Age-adjusted incidence rates for all histologic types were significantly 
higher for men than for women, but adenocarcinoma represented a larger proportion of lung 
cancers in women (41%) than in men (34%). The sex differences in rates of adenocarcinoma 
and small cell carcinoma were less pronounced than the differences observed for other 
histologic types (Table 2).
Tables 3 and 4 present incidence rates by histologic type for men and women by age, race/
ethnicity, and U.S. Census region. Among men, the incidence of squamous cell carcinoma 
and adenocarcinoma were higher for NH blacks than for NH whites; among women, 
differences by race/ethnicity were less pronounced. Histologic incidence rates for NH 
AI/AN men and women were lower compared to NH white and NH black. Rates for small 
cell carcinoma in NH AI/AN women exceeded those for NH black women (Table 4). Data 
stratified by region showed a higher incidence of adenocarcinoma for men than for women 
in all regions, but differences in rates were smaller between men and women living in the 
West.
Temporal trends of total lung cancer incidence rates from 2004–2009 for men and women 
stratified by age (<50 years and ≥50 years) revealed a less rapid decrease in women than in 
men (Figure 1). Age-adjusted incidence rates for lung adenocarcinoma significantly 
increased for both men and women, and increased more rapidly for women than for men 
(Figure 2). Among adults aged 50 years or older, incidence trends for lung adenocarcinoma 
showed a significant decreasing trend for men (APC = −1.6%) and a significant increasing 
trend for women (APC = 3.2%) (data not shown). Age-adjusted incidence rates for 
squamous cell carcinoma increased in women but stabilized in men (Figure 2). Among those 
younger than age 50 years, incidence trends for squamous cell carcinoma significantly 
decreased in men (APC = −4.5%) but not in women (APC = −0.3%; P = 0.7), but for adults 
aged 50 years or older, rates significantly increased in women (APC = 2.0%) but stabilized 
in men (APC = −0.1%; P = 0.6) (data not shown).
DISCUSSION
Our study shows that, during 2004–2009 in the U.S., the overall incidence of lung cancer 
significantly decreased among men and remained stable among women, and trends differed 
by histologic type. Increases in adenocarcinoma and squamous cell carcinoma for women 
were partially offset by decreases in other types of NSCLC. Consistent with findings from 
previous studies, we found that rates for small cell carcinoma were higher among white men, 
but rates for other histology types were highest among black men. Histologic rates among 
women were similar for black and white women; however, the rate for small cell carcinoma 
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in white women was nearly two times higher than the rate for black women. We found that 
the rates for all histologic types were lowest in the West region, an area comprised of states 
that have the lowest percentage of smokers (20). Among men and women, the rate of 
adenocarcinoma was highest in the northwest region. Small cell carcinoma rates were 
highest in the Midwest and South regions.
The shift in lung cancer trends by histologic type that has occurred over the last several 
decades—specifically, adenocarcinoma becoming more prevalent than squamous cell 
carcinoma (8, 10) —has been hypothesized to be due to changes in cigarette composition 
and design (19–22). The addition of ventilated filters to cigarettes changed the way smokers 
smoked, causing them to inhale smoke more vigorously into the peripheral lung, where 
adenocarcinomas are commonly found (20, 21, 23). However, a study that examined the 
tumors of smokers of lower-tar cigarettes and smokers of higher-tar cigarettes failed to find 
an association between tar dosage and lung adenocarcinoma and squamous cell carcinoma 
cell types (24). Another factor could be changes in the composition of cigarettes; the levels 
of tobacco-specific nitrosamines, particularly potent lung carcinogen 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in U.S. cigarettes have increased over 
the past 3 decades (20, 25).
The recent trends observed in our study occurred about the same time as changes in rules for 
classifying lung cancer histology (2–4) and advances in lung cancer treatment that require 
accurate classification (5, 6). These changes may have led to fewer NSCLCs being classified 
as “other” and instead classified more accurately as adenocarcinoma or squamous cell 
carcinoma, which may partially explain the increases we observed in these histologic types.
Cigarette smoking is a causal determinant of lung cancer, and because the epidemic of 
tobacco use began earlier in men than in women, men historically have had higher lung 
cancer rates than women (26). However, because of diminishing differences in smoking 
patterns between men and women, the gender gap in lung cancer is also diminishing (26–
28). We found that, among adults aged 50 years or older, lung cancer incidence rates for men 
were higher than for women; this difference was greatest among the oldest and diminished 
with decreasing age. However, among those younger than age 50 years, women had higher 
rates than men, particularly for adenocarcinoma.
A report based on data from just the SEER registries showed that lung cancer rates for all 
histologic types increased among women during 1969–1991 (11). Our study showed that 
lung adenocarcinoma and squamous cell carcinoma rates increased, but that small cell 
carcinoma and large cell carcinoma rates decreased during 2004–2009 among women. The 
increasing rates of adenocarcinoma and squamous cell carcinoma observed in this study are 
consistent with earlier trends reported in previous studies (8, 11). Our data for women under 
age 50 did not show the early signs of decline in adenocarcinoma rates that have been 
observed among women born after 1950 in Canada, Denmark, and Australian (29). Other 
authors have suggested that later uptake of cigarette smoking and less rapid decrease in 
smoking prevalence among women than men (27, 28, 30) might partially explain the 
increasing rates of squamous cell carcinoma in women. Cigarette smoking is involved in the 
etiology of most lung cancers, but the etiologic mechanism may differ by histologic type 
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(31, 32). Compared with other histologic types, squamous cell lung cancers had previously 
been found to be more strongly associated with heavy smoking (33–35).
To date, few studies have examined age-specific sex differences in lung cancer rates by 
histologic type. Previous analyses have suggested that lung cancer rates in men exceed those 
in women for all histologic types (8, 11). However, this study found among those younger 
than age 50 years the rate of adenocarcinoma was higher in women than in men. In addition 
to cigarette smoking, several factors have been identified as potential risk factors for lung 
adenocarcinoma, including cooking oil fumes, hormones, menstrual cycles, and pregnancy 
(36–41). More recent evidence suggests other risk factors such as human papillomavirus 
infection (42) and indoor and outdoor air pollution (15) are associated with increased risk 
for lung adenocarcinoma, but etiologic mechanisms and causal associations remain unclear.
Previous studies that examined incidence trends by histologic type and by race and sex 
during 1969–1986 showed higher rates of squamous cell carcinoma in blacks than in other 
racial/ethnic groups and higher rates of adenocarcinoma in black men than in men in other 
racial/ethnic groups (8). In our results, rates of squamous cell carcinoma and 
adenocarcinoma were highest in non-Hispanic black men, and the rate of adenocarcinoma 
was higher in NH white women compared to women in other racial/ethnic groups. 
Consistent with a recent study (43) our results show that compared to NH whites, lung 
cancer incidence rates for Hispanics were substantially lower. Consistent with previously 
reported data, our results showed overall lung cancer rates for NH AI/AN were lower than 
rates for NH blacks and NH whites. Among women, small cell lung cancer was more 
common among NH AI/AN than among NH black women, and differences in cigarette use 
and geographical location might explain some of these observed differences (44, 45).
In 2011, a joint working group of the International Association for the Study of Lung 
Cancer, American Thoracic Society, and European Respiratory Society introduced a new 
adenocarcinoma classification to better distinguish pre-invasive, minimally invasive, and 
invasive adenocarcinoma (46–47). Additional research is needed to better understand the 
correlation between lung cancer histology and the results observed on lung cancer screening 
with low dose spiral computed tomography LDCT. In the initial round of screening of study 
participants in the the National Lung Screening Trial (NLST), lung cancer screening with 
low-dose computed tomography (LDCT) identified a higher proportion of adenocarcinoma 
than squamous cell carcinoma (48–51). Questions for future research might include the 
potential frequency of over diagnosis of indolent lung cancer cases that would not become 
clinically apparent (52) and whether LDCT screening has a uniform ability to detect all 
histologic types of lung cancer or a uniform effect on death and survival rates across all 
histologic types (53). Such research would provide information that informs 
recommendations for discussions with clinicians about potential limitations and harms 
associated with screening for lung cancer with LDCT (54, 55).
The findings in this study are subject to the following limitations. First, our results provide 
estimates of incidence rates and trends by histologic type for the entire U.S. population, but 
we were unable to examine incidence by smoking because smoking data are not consistently 
collected in U.S. cancer registries. Second, analyses based on race and ethnicity, particularly 
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among NH AI/AN, might be biased if race and ethnicity were misclassified; efforts were 
made to ensure that this information was as accurate as possible (56, 57).
CONCLUSION
Our study provides an update on lung cancer incidence trends by histologic type and 
expands previous research by providing age, race/ethnicity and sex-specific trends for the 
entire United States. The continued examination of lung cancer by histological subtype is 
important because the etiology, detection, diagnosis and treatment of lung cancer may differ 
by type and can change over time. The variations observed by race and ethnicity, the 
continuing rise in lung adenocarcinoma, and the rise of squamous cell cancer in women 
point to important knowledge gaps in our understanding of factors that operate in addition 
to, or in combination with, smoking to impact lung cancer incidence rates in the United 
States.
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Figure 1. 
Lung Cancer Incidence Trends by Sex and Age—United States, 2004–2009a
Data are from population-based registries that participate in the National Program of Cancer 
Registries and/or the Surveillance, Epidemiology, and End Results and meet high-quality 
data criteria. These registries cover approximately 98% of the U.S. population.
a Rates are per 100,000 and age-adjusted to the 2000 U.S. Std Population (19 age groups—
Census P25-1130) standard
* Annual percent change (APC) is significantly different from zero (p<0.05)
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Figure 2. 
Lung Cancer Incidence Trends by Sex: Small Cell vs. Non-Small Cell Lung Cancer 
Subtypes—United States, 2004–2009a
Data are from population-based registries that participate in the National Program of Cancer 
Registries and/or the Surveillance, Epidemiology, and End Results and meet high-quality 
data criteria. These registries cover approximately 98% of the U.S. population.
Lung cancer histology groups were defined using International Classification of Diseases for 
Oncology version 3 (ICD-0-3): non-small cell carcinoma (8010-8015, 8020-8022, 
8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 
8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 
8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941), small cell carcinoma 
(8041-8045). Non-small cell carcinomas were further categorized as squamous cell 
(8051-8052, 8070-8084, 8120-8131), adenocarcinoma (8050, 8140-8149, 8160-8162, 
8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 
8940-8941), large cell carcinoma (8011-8015), and Other non-small cell carcinoma (8010, 
8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 
8240-8249, 8340-8347, 8561-8562, 8580-8671).
a Rates are per 100,000 and age-adjusted to the 2000 U.S. Std Population (19 age groups—
Census P25-1130) standard
* Annual percent change (APC) is significantly different from zero (p<0.05)
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